Thomas Catinazzo Sells 36,036 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 36,036 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $4.63, for a total value of $166,846.68. Following the completion of the sale, the chief financial officer now owns 263,190 shares of the company’s stock, valued at approximately $1,218,569.70. The trade was a 12.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Thomas Catinazzo also recently made the following trade(s):

• On Thursday, January 30th, Thomas Catinazzo sold 20,791 shares of Relay Therapeutics stock. The stock was sold at an average price of $4.42, for a total transaction of $91,896.22.
• On Friday, December 27th, Thomas Catinazzo sold 4,865 shares of Relay Therapeutics stock. The shares were sold at an average price of $4.42, for a total transaction of $21,503.30.

Relay Therapeutics Price Performance

Shares of RLAY opened at $4.54 on Friday. Relay Therapeutics, Inc. has a 52 week low of $3.50 and a 52 week high of $11.16. The stock has a 50 day moving average price of $4.53 and a two-hundred day moving average price of $6.12.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.14. Relay Therapeutics’s quarterly revenue was down 100.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.54) EPS. On average, equities analysts anticipate that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current year.

Wall Street Analyst Weigh In

RLAY has been the subject of several research analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price target on shares of Relay Therapeutics in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Relay Therapeutics in a research report on Tuesday, January 14th. Finally, Leerink Partners cut their price target on Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, December 4th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.50.

Institutional Trading of Relay Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Congress Asset Management Co. increased its stake in Relay Therapeutics by 7.6% in the 4th quarter. Congress Asset Management Co. now owns 157,485 shares of the company’s stock valued at $649,000 after buying an additional 11,061 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Relay Therapeutics by 8.6% in the fourth quarter. Rhumbline Advisers now owns 171,444 shares of the company’s stock valued at $706,000 after acquiring an additional 13,532 shares in the last quarter. Savant Capital LLC purchased a new stake in shares of Relay Therapeutics during the fourth quarter valued at approximately $120,000. China Universal Asset Management Co. Ltd. lifted its holdings in Relay Therapeutics by 37.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 35,491 shares of the company’s stock worth $146,000 after acquiring an additional 9,740 shares during the period. Finally, SG Americas Securities LLC boosted its position in Relay Therapeutics by 40.8% in the fourth quarter. SG Americas Securities LLC now owns 77,557 shares of the company’s stock worth $320,000 after purchasing an additional 22,473 shares during the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.